Lupin Q2 Hit By US Settlement, Japan Injectables Selloff
Goa, Somerset Plants Up For Re-inspection Jan-Mar
Despite 10% revenue growth, Lupin ends up with a second-quarter loss from a one-time charge from settling a US lawsuit and the sale of its Japan injectables business. It's now counting on levothyroxine and secnidazole to carry it through the next few quarters, amid speculation that it might divest its Japanese subsidiary.
